Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

3.

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID:
12529347
4.

Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.

Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P.

Cancer Res. 1995 May 15;55(10):2104-10.

5.

Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.

Yu H, Levesque MA, Clark GM, Diamandis EP.

Clin Cancer Res. 1998 Jun;4(6):1489-97.

6.
8.

Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.

J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65.

PMID:
15601642
9.

Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.

Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA.

Cancer. 2004 Oct 1;101(7):1490-500.

10.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
11.
13.

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.

Br J Cancer. 1999 Feb;79(5-6):888-94.

14.

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I.

Breast Cancer Res Treat. 2005 May;91(1):81-7.

PMID:
15868434
15.

Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.

Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY, Sauter ER, Diamandis EP.

Br J Cancer. 2000 Jan;82(2):361-7.

16.

Prostate-specific antigen value as a marker in breast cancer.

Narita D, Cimpean AM, Anghel A, Raica M.

Neoplasma. 2006;53(2):161-7.

PMID:
16575473
17.
18.

Incidence of estrogen, progesterone and prolactin receptors in human breast cancer.

Calandra RS, Charreau EH, Royer de Giaroli M, Baldi A.

Prog Clin Biol Res. 1984;142:97-108.

PMID:
6709661
19.

Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.

Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M.

Cytometry B Clin Cytom. 2005 Mar;64(1):43-52.

20.

Loss of expression of a 55 kDa nuclear protein (nmt55) in estrogen receptor-negative human breast cancer.

Traish AM, Huang YH, Ashba J, Pronovost M, Pavao M, McAneny DB, Moreland RB.

Diagn Mol Pathol. 1997 Aug;6(4):209-21.

PMID:
9360842

Supplemental Content

Support Center